Marder S R, Hawes E M, Van Putten T, Hubbard J W, McKay G, Mintz J, May P R, Midha K K
Psychopharmacology (Berl). 1986;88(4):480-3. doi: 10.1007/BF00178510.
Plasma fluphenazine concentrations (FLU) were measured in 45 patients with schizophrenic disorders who participated in a double-blind comparison of 5 and 25 mg fluphenazine decanoate (FD). The rise in plasma level of FLU 24 h after a "test dose" was significantly correlated with steady state FLU concentration at 12 weeks (for 5 mg patients, r = 0.45, P = 0.04; for 25 mg, r = 0.78, P = 0.005). Patients who had low FLU at baseline required nearly 6 months to reach a steady state when they received 25 mg. Patients who received 5 mg and had low FLU at baseline continued to demonstrate relatively low plasma levels for the entire 1st year. Although the mean FLU at 6 months was lower for patients who relapsed during the subsequent 18 months (0.57 ng/ml for relapsers vs 1.01 ng/ml for nonrelapsers), this difference was not statistically significant. When plasma levels from both dosage groups were combined, FLU at 12 weeks correlated significantly with factor scores for akinesia (r = 0.52, P = 0.002) and BPRS cluster scores for retardation (r = 0.52, P = 0.002). These results indicate that the measurement of fluphenazine plasma levels may be useful in determining when patients treated with FD are receiving drug doses which are likely to cause discomforting side effects.
对45名参与癸酸氟奋乃静（FD）5毫克和25毫克双盲比较研究的精神分裂症患者测定了血浆氟奋乃静浓度（FLU）。“试验剂量”后24小时FLU血浆水平的升高与12周时的稳态FLU浓度显著相关（5毫克组患者，r = 0.45，P = 0.04；25毫克组，r = 0.78，P = 0.005）。基线时FLU水平低的患者接受25毫克剂量时，需要近6个月才能达到稳态。基线时接受5毫克剂量且FLU水平低的患者在整个第1年血浆水平仍相对较低。尽管在随后18个月内复发的患者6个月时的平均FLU水平较低（复发者为0.57纳克/毫升，未复发者为1.01纳克/毫升），但这种差异无统计学意义。当将两个剂量组的血浆水平合并时，12周时的FLU与运动不能因子评分（r = 0.52，P = 0.002）和BPRS迟缓聚类评分（r = 0.52，P = 0.002）显著相关。这些结果表明，测定氟奋乃静血浆水平可能有助于确定接受FD治疗的患者何时接受了可能导致不适副作用的药物剂量。
